Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Revumenib (SNDX-5613) in Relapsed/Refractory Acute Leukemias With KMT2A Rearrangement or NPM1 Mutation
2020-004104-34Phase 2Active
- Sponsor
- Syndax Pharmaceuticals
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of revumenib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), Acute Leukaemia and 1 more, sponsored by Syndax Pharmaceuticals. Started Sep 2021; status: active.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)Acute Leukaemialeukemia
Beyond the preview
Go deeper on 2020-004104-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004104-34.